U.S. markets closed

Edesa Biotech, Inc. (EDSA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.39+0.04 (+0.75%)
At close: 04:00PM EST
5.50 +0.11 (+2.04%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close5.35
Bid5.16 x 1300
Ask5.38 x 3100
Day's Range5.00 - 5.49
52 Week Range4.05 - 12.00
Avg. Volume3,392,446
Market Cap71.662M
Beta (5Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)-1.05
Earnings DateFeb 14, 2022 - Feb 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for EDSA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Edesa Biotech, Inc.
    Analyst Report: McDonald's CorporationMcDonald’s Corporation is the largest restaurant owner-operator in the world, with 2020 systemwide sales of $93 billion across 39,000 stores and 119 countries. McDonald’s revolutionized the restaurant industry with a cheap and fast core menu, building its impressive footprint through partnerships with independent restaurant franchisees. The firm earns 57% of its revenue from franchise royalty fees and lease payments, with the remainder coming from company-operated stores across its three core segments: the United States, internationally operated markets, and international developmental/licensed. McDonald’s owns 55% of the real estate and 80% of the buildings in its franchise system, offering it substantial leverage in maintaining quality standards and consistency across markets.
    Fair Value
    Economic Moat
    7 months agoMorningstar
View more

    Edesa Biotech Marks Enrollment Milestone in Dermatitis Study

    TORONTO, ON / ACCESSWIRE / December 1, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of more than 75% of the patients planned for the primary cohort of a Phase 2b clinical study evaluating the company's drug candidate, designated EB01, as a monotherapy for chronic allergic contact dermatitis.


    Edesa Biotech Extends COVID-19 Clinical Study to Poland

    * Expansion to European Union country follows favorable Phase 2 results * Company focusing on critically ill hospitalized patientsTORONTO, ON / ACCESSWIRE / November 4, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that Polish regulators have approved a clinical trial application for the investigational use of the company's monoclonal antibody candidate, designated EB05, as a single-dose t

  • Zacks Small Cap Research

    EDSA: Additional Favorable Mortality Reductions Identified in COVID-19 Trial…

    By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Additional Mortality Benefits Identified in Phase 2 COVID-19 Trial On October 19, 2021, Edesa Biotech, Inc. (NASDAQ:EDSA) announced additional results from the Phase 2 portion of the ongoing Phase 2/3 clinical trial of EB05 in critically ill COVID-19 patients. Last month, the independent Data and Safety Monitoring